Friess Associates’s AstraZeneca AZN Stock Holding History

Friess Associates’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-209,000	Closed	-$20.8M	–	105
2019 Q4	$20.8M	Hold	209,000	–	–	1.45%	28
2019 Q3	$18.6M	Hold	209,000	–	–	1.44%	34
2019 Q2	$17.3M	Buy	209,000 +7,500	+4%	+$588K	1.26%	36
2019 Q1	$16.3M	Sell	201,500 -545	-0.3%	-$43K	1.19%	42
2018 Q4	$15.3M	Buy	+202,045	New	+$15.8M	1.31%	37

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Friess Associates's AZN Position: Q1 2020 in Review

Friess Associates sold out of AstraZeneca (AZN) in Q1 2020, closing a stake of 209,000 shares — an estimated $20.8M sold.

Friess Associates first reported a position in AZN in Q4 2018 and held it in 5 quarters. The position peaked at $20.8M in Q4 2019. 603 funds tracked by Wall St. Rank hold AZN as of Q1 2020.

Friess Associates reported no remaining AstraZeneca position as of Q1 2020 after selling out during the quarter.
Friess Associates sold 209,000 AstraZeneca shares in Q1 2020, an estimated $20.8M.
Friess Associates first reported a position in AstraZeneca in Q4 2018 and held it in 5 quarters.
Friess Associates's AstraZeneca position peaked at $20.8M in Q4 2019.
603 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2020.

Based on Friess Associates's 13F filing for Q1 2020, filed 15 May 2020.